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"COME, LET US RETURN TO REASON":
ASSOCIATION OF MOLECULAR PATHOLOGY V.
USPTO
I.

INTRODUCTION

Almost 30 years ago, an impassioned group of
scientists, "among them Nobel laureates," urged the
U.S. Supreme Court that, if genetic technology
were allowed to be made the subject of a patent, a
"gruesome parade of horribles" would follow. The
Court wisely rejected such arguments. Instead it
endorsed an "expansive" construction of 35 U.S.C.
§ 101, and affirmed the patent-eligibility of the
genetic technology at issue there. The gruesome
parade never materialized.
Instead, the
biotechnology industry has grown up and flourished
under this legal regime.1
When discussing the recent explosion of the biotechnology
industry, the term "flourished" is putting it mildly. "In the
healthcare sector alone, the industry has developed and
commercialized more than 300 biotechnology drugs and hundreds
of diagnostics that are helping more than 325 million people
worldwide; another 400 or so biotechnology products are in the
pipeline."2
Much of this growth is attributed to patents.
Nevertheless, in May of 2009, a group of plaintiffs re-sounded the

1. Myriad Defendant's Memorandum of Law (1) In Support of their Motion
for Summary Judgment and (2) In Opposition to Plaintiffs' Motion for
Summary Judgment at 1, Ass'n for Molecular Pathology v. USPTO, No. 094515 (S.D.N.Y. filed December 23, 2009), availableat http://docs.justia.com/
cases/federal/district-courts/new-york/nysdce/1:2009cv04515/345544/153/
(citing Diamond v. Chakrabarty, 447 U.S. 303, 316-17 (1980)) (hereinafter
Myriad Memo).
2. Letter from James Greenwood, President and CEO of Bio, to Darren
Greninger at
the National Institutes
of Health,
available at
http://bio.org/ip/domestic/documents/SACGHSBIOComments5-09.pdf
(hereinafter Bio Letter).
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"Chicken-Little" alarms3 and flooded the media with reports that
the sky was falling in the context of gene patents. Although gene
patents have always generated a substantive amount of debate, the
recent filing of Association for Molecular Pathology, et al. v.
United States Patent and Trademark Office4 in the Southern
District of New York (SDNY), undoubtedly stepped up the
intensity of such concerns. By organizing and filing this lawsuit,
the American Civil Liberties Union (ACLU), seeks not only to
invalidate a series of patents related to two genes known to
correlate to breast and ovarian cancer, but also file an
unprecedented action against the United States Patent and
Trademark Office (USPTO), seeking the court to issue a
categorical ban on patents claiming human genes. Judge Sweets of
the United States District Court for the Southern District of New
York, who has been assigned to this case, should follow the
guidance of Judge Rich, who, when approached with identical
concerns almost thirty years ago, declared: "Come, let us return to
5
reason."
The question of whether patents should be granted on human
DNA is a controversial issue that has the whole world split, and it
seems everybody has something to say about it. Of course, public
debate and discussion of social policy issues is something to be
encouraged; however, when the majority of the arguments are
based on misinformation, the debate becomes harmful to society.
Unfortunately, rather than choosing to tackle the practical concerns
head-on, numerous gene-opponents have been known to rely on
sensationalized and dramatic arguments. One example of this is
Michael Crichton's infamous editorial in the New York Times
declaring: "YOU, or someone you love, may die because of a gene
3. See Chakrabarty,447 U.S. at 316-17.
4. Complaint, Ass'n for Molecular Pathology v. U.S. Patent & Trademark
Office, No. 09-4515 (S.D.N.Y. filed May 12, 2009) available at
http://docs.justia.com/cases/federal/district-courts/new-york/nysdce/1:2009cv
04515/345544/1/ (hereinafter Compl.).
5. In re Bergy, 596 F.2d 952, 984 (C.C.P.A. 1979). Before dismissing the
PTO's entire argument, Judge Rich responded to the Commissioner's concerns
with: "'The sky is falling, the sky is falling!' cried Chicken Little. The CCPA is
indulging in 'wholesale judicial legislation,' says the solicitor, by 'extending'
the patent laws to 'encompass living organisms-life itself.' Come let us return to
reason." Id.
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patent that should never have been granted in the first place. Sound
far-fetched? Unfortunately, it's only too real. "6
Rather than choosing to lead a well-informed public debate that
utilized reasoned arguments and a careful analysis of the facts, the
ACLU chose to lay out a high-profile campaign relying on the
emotional appeal of both cancer and civil rights. This lawsuit has
become transformed into a high-profile publicity campaign that
quickly attracted the attention of both the media and the public,
illustrating the natural tendency of humans "to jump to conclusions
and demand immediate solutions. '7 As litigation tends to do, the
filing of this suit has further polarized the already divisive issue.
Rather than examining alternative solutions, the ACLU has
demanded that all gene patents be declared invalid and that the
Patent Office be banned from issuing such patents.
There are clear policy interests at stake for both sides. Patents
that claim innovative medical technologies raise a multitude of
new concerns. The long-term goals of the patent system do not
always directly align with the short-term needs of patients. Myriad
is one example of this. This suit, singled out a series of patents on
BRCA1 and BRCA1, often referred to as the "breast cancer
genes,"8 and was specifically directed against Myriad Genetics, the
exclusive licensee of these patents. As a result of the BRCA
patents, Myriad Genetics has the exclusive right to commercialize
the BRCA diagnostic test, thus allowing them set the cost of their
test without concern of competitors drawing much critique of the
gene patenting practice altogether.9 The ACLU did not stop with

6. Michael Crichton, Op-Ed., Patenting Life, N.Y. TIMES, Feb. 13, 2007, at
A23, availableat http://www.nytimes.com/2007/02/13/opinion/l 3crichton.html.
7. Sigrid Fry-Revere & David Bjorn Malmstrom, Special Supplement:
Dangerous Liaisons? Industry Relations with Health Professionals: More
Regulation of Industry-SupportedBiomedical Research: Are we asking the right
questions?, 37 J.L. MED. & ETHICs 420 at 427 (2009).

8. These patents seek to patent isolated and purified human genes, mutations
in those genes, and correlations between those mutations and an increased risk
of breast or ovarian cancer; see U.S. Patent No. 5,747,282 (filed June 7, 1995);
U.S. Patent No. 5,710,001 (filed June 7, 1995).

9. The BRCA patents implication on patients' access to their diagnostic
testing has generated much public critique. See, e.g. Emma Woollacott, Civil
liberties group files landmark gene patenting case, TG DAILY, May 15, 2009

(quoting Yvonne Cripps, the Harry T Ice Professor of Law at Indiana University

Published by Digital Commons@DePaul, 2016

3

DePaul Journal of Art, Technology & Intellectual Property Law, Vol. 20, Iss. 2 [2016], Art. 9

476

DEPA UL J. ART, TECH & IP LAW

[Vol. XX:2

naming Myriad Genetics as a defendant. In a radical attempt to
invalidate all gene patents and eliminate similar patents from being
granted in the future, ACLU challenges the constitutionality of the
formal written policy of the USPTO. " If the ACLU are successful
in their claim, it would "frustrate decades of investments in
research and development undertaken in reliance on DNA patents
and established legal precedent relating thereto, and, going
forward, would destroy perhaps the most important incentive for
investing in DNA-based inventions."'"
The complicated intricacies of this debate involve technological
advancements, public policy concerns, and constitutional rights;
this is not the place for philosophical arguments. Rather, the more
appropriate analysis of such patents should consider practical
arguments that take into consideration realistic consequences. The
fact that not all women can afford the diagnostic tests offered by
Myriad Genetics goes against instinctual notions of equity.
However, the ACLU has failed to offer any legal argument that
warrants a categorical ban on gene patents as a whole.
The aim of this article is to tackle the legal merits and the factual
basis of ACLU's complaint in Myriad. Part II will discuss the
relevant background at issue, including the history of
biotechnology, patent law, and gene patents. Part III will discuss
the complaint filed in Myriad, as well as the district court's denial
of the defendants' motions to dismiss. Part IV will analyze each of
the ACLU's causes of action and discuss why the ACLU's
arguments against gene patents lack a sufficient basis in fact or
law.

Maurer School of Law:

"The patents have already been questioned

internationally because of their fundamental importance .... they affect, in
various ways, access to potentially life-saving medical treatment.").
10. The complaint at issue states: "[a]lthough the sequences are dictated by
nature, the variants are dictated by nature, and the significance of the variants is
dictated by nature, the USPTO has a policy and practice of issuing such
patents." Compl., supra note, 50.
11. Brief for Amicus Curiae Biotechnology Industry Organization in Support
of Defendants' Opposition to Plaintiffs' Motion for Summary Judgment, AMP,
No.

09-4515,

available

at

http://docs.justia.com/cases/federal/district-

courts/new-york/nysdce/1:2009cv04515/345544/183 (hereinafter BIO Brie).
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II. BACKGROUND

A.

Genomics

The discovery of the molecular structure of DNA 12 in 1953
marked the beginning of a revolutionary whirlwind of significant
advancements in biotechnology. 3
This ground-breaking
discovery, which revealed the double helical structure of DNA,
immediately suggested that DNA was the master molecule
containing the biological instructions needed for an organism to
develop, survive and reproduce. 4 Human genes are discrete
sequences of DNA molecules and are composed of unique
combinations of four different types of nucleotides, each named
after their nitrogen base: adenine (A), thymine (T), guanine (G)
and cytosine (C). 15 The order of these four bases in a DNA strand
12. "DNA, which stands for deoxyribonucleic acid, is a chemical compound
made by the body." AMP, No. 09-4515, at 24 (S.D.N.Y. Nov. 1, 2009) (order
denying motion to dismiss) availableat http://docs.justia.com/cases/federal/
district-courts/new-york/nysdce/1:2009cv04515/345544/140 (hereinafter Order
Denying Motion to Dismiss).
13. See Watson J.D. & Crick F.H.C. A Structurefor Deoxyribose Nucleic
Acid, 171 NATURE 737 (1953), availableat http://www.nature.com/nature/
dna50/watsoncrick.pdf. The structure of DNA was first determined by Watson
and Crick, who revealed this discovery in a 1953 paper describing the structure
of DNA as having "novel features which are of considerable biological
interest." Id.; see also Mary Kay Pelias & Nathan J. Markward, The Human
Genome in the Public View: Genetics, Geneticists, and Eugenics, 13 ST.
THOMAS L. REv. 827, 843 (2001) (noting the "explosion of technologies over
the past two decades has created a new environment for genetics research").
14. "The DNA molecule consists of two strands that wind around one
another to form a shape known as a double helix." Genetic Home Reference,
http://ghr.nlm.nih.gov/handbook/basics/dna (last visited Feb. 10, 2010); see also
Genome
News
Network,
Genetics
and
Genomics
Timeline,
http://www.genomenewsnetwork.org/resources/timeline/1953_CrickWatson.ph
p (last visited Feb. 10, 2010); National Human Genome Research Institute,
National Institutes of Health, http://www.genome.gov/25520880 (last visited
Feb. 10, 2010).
15. See Order Denying Motion to Dismiss, supra note 12, at 24; see also
National Human Genome Research Institute, National Institutes of Health,
http://www.genome.gov/25520880 (last visited Feb. 10, 2010) (explaining that
"DNA, along with the instructions it contains, is passed from adult organisms to
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is referred to as a molecule's 'DNA sequence', 'nucleotide
sequence', or 'structural formula." 6 "The sequence of each gene
reflects the strings of hundreds or thousands of A, T, C, and G
nucleotides that make up the gene." 7 It is this sequence that
determines what biological instructions are contained in a strand of
DNA and enables researchers to "determine which stretches of
DNA contain genes, as well as to analyze those genes for changes
in sequence, called mutations, that may cause disease."18
Gene sequencing is one method by which medical professionals
and researchers can examine genes.' 9 By the mid-1970's scientists
were able to isolate individual genes and determine their chemical
composition." Subsequent advancements in genetic technologies
resulted in the establishment of several hundred small
biotechnology companies during the late-1970's and 1980's."i In
their offspring during reproduction" and that "organisms inherit half of their
nuclear DNA from the male parent and half from the female parent").
16. Andrew Chin, Research in the Shadow of DNA Patents, 87 J. PAT. &
TRADEMARK OFF. SOC'Y 846, 849 (2005).
17. OrderDenying Motion to Dismiss, supra note 12, at 24.

18. National Human Genome Research Institute, National Institutes of
Health, http://www.genome.gov/10001177 (last visited Feb. 10, 2010); see also
Debra Greenfield, Intangible or Embodied Information: The Non-Statutory
Nature of Human Genetic Material, 25 SANTA CLARA COMPUTER & HIGH
TECH. L.J. 467 (2009):
The arrangement of these four bases . . . determines the

nature, functionality, and often the health of an organism...
.[the genome] can store enormous amounts of information by
the almost endless repetition of very simple operations .... it
is a four-way choice . . . repeated over and over, 3 billion

times in the human genome.
Id.at 480.
1'9. Plaintiffs' Memorandum of Law in Support of Motion for Summary
Judgment

at 2, AMP, No. 09-4515 (S.D.N.Y.

filed August 26, 2009),

http://docs.justia.com/cases/federal/district-courts/new-york/nysdce/1:2009cv
04515/345544/62/ (hereinafter PL.'s Memo).
20. BOARD ON SCIENCE, TECHNOLOGY, AND ECONOMIC POLICY, REAPING
THE BENEFITS OF GENOMIC AND PROTEOMIC RESEARCH: INTELLECTUAL
PROPERTY RIGHTS, INNOVATION, AND PUBLIC HEALTH 19 (Stephen A. Merrill &

Anne-Marie Mazza eds., The National Academies Press) (2006), available at
http://www.nap.edu/openbook. php?recordid= 11487&page= 19.
21. NUFFIELD COUNCIL ON BIOETHICS, THE ETHICS OF PATENTING DNA ch.1,

1.6

at

4

(Nuffield
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1986, the development of an automated technique for sequencing
DNA made gene sequencing feasible, marking an essential
development for genomics.22
The year 2001 marked the
completion of the Human Genome Project (HGP), a coordinated
research project created to sequence the entire collection of human
genetic material, a total of approximately three billion base pairs
and approximately 30,000 genes in total.23 At the project's
conclusion, the draft map of the human genome was published,
disclosing its entire sequence 24; however, our understanding of the
human genome was just beginning. Currently, it is estimated that
the functions remain unknown for over fifty percent of discovered

genes.26
Our understanding of genes is particularly important because
athttp://www.nuffieldbioethics.org/fileLibrary/pdf/theethicsofpatentingdna.pdf.
22. Genetics and Genomics Timeline, GENOME NEWS NETWORK,
http://www.genomenewsnetwork.org/resources/timeline/1986_Hood.php
(last
visited Feb. 10, 2010). During the next thirteen years, this automated
sequencing machine was constantly improved, and by 1999 a fully automated
instrument could sequence up to 150,000,000 base pairs per year. Id.
23. See Genetics and Genomics Timeline, GENOME NEWS NETWORK,
http://www.genomenewsnetwork.org/resources/timeline/1986_1990 sequencehuman.php; see also, Eileen M. Kane, Splitting the Gene: DNA Patents and the
Genetic Code, 71 TENN. L. REv. 707, 710 (2004). "The genome is the entire
DNA sequence, annotated to indicate where the genes are located along the
length of the DNA." Id. at 722 n.77.
24. Regarding such publication:
Two versions of the map of the human genome sequence were
published .

. .

. The public sector human genome project

published the sequence in Nature (see Lander ES et al. Initial
sequencing and analysis of the human genome. Nature 2001
Feb 15;409(6822):860-921); while the private sector project
undertaken by Celera Inc, a US genomics company, was
published in Science (see Venter JC et al. The sequence of the
human genome. Science 2001 Feb 16;291(5507):1298-302).
NUFFIELD COUNCIL ON BIOETHICS, supra note 21, ch. 1, 1.1 at 3 n. 1.
25. Only about two percent of the human genome consist of genes; "the
remainder consists of noncoding regions, whose functions may include
providing chromosomal structural integrity and regulating where, when, and in
what quantity proteins are made." The Science Behind the Human Genome
Project,
From the
Genome
to
the
Proteome,
available at
http://www.oml.gov/sci/techresources/HumanGenome/proj ect/info.shtml (last
visited Feb. 10, 2010).
26. Id.
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many genes play a role in human disease; 27 more than 4,000
inheritable diseases stem from mutated genes.28
Promising
advancements within the past three decades have made it possible
for scientists to link particular genes to specific diseases, create
diagnostic tests and gene therapies, as well as improve the
diagnosis of genetic disorders. 29 "Once scientists have linked a
gene to a disease, predictive gene tests can be developed and used
to identify individuals who are at risk of getting the disease."3 °
In general, nucleotide bases are exactly the same in all people;"
however, the sequence of any given human gene sometimes varies
from one person to another.12 These alterations can be inherited or
can occur after birth.33 Although some of the alterations seem to
be unimportant, others correlate with an increased risk of disease
or disorder and are called mutations.34 Diagnostic testing is the
process of examining an individual's genes to see if he or she has
alterations known to be of clinical significance.35
B. PatentLaw
President Abraham Lincoln, a strong supporter of patents, stated
that "[tihe patent system. . . added the fuel of interest to the fire of
genius."" Lincoln, a patent holder himself, recognized a key
feature of the patent system: the stimulation of scientific
27. NUFFIELD COUNCIL ON BIOETHICS, supra note 21, ch.1, 1.1 at 3.
28. Biotechnology Industry Organization, National Issues, Intellectual
Property, available at http://www.bio.org/ip/primer/genehelps.asp (last visited
Feb. 10, 2010).
29. See Molly A Holman & Stephen R. Munzer, IntellectualProperty Rights
in Genes and Gene Fragments:A Registration Solutionfor Expressed Sequence
Tags, 85 IOWA L. REv. 735 (2000).
30. Biotechnology Industry Organization, supra note 28.
31. "Almost all (99.9%) nucleotide bases are exactly the same in all people."
The Science Behind the Human Genome Project, From the Genome to the
Proteome, availableat http://www.oml.gov/sci/techresources/Human-Genome/
project/info.shtml (last visited Feb. 10, 2010).
32. OrderDenying Motion to Dismiss, supra note 12, at 24.
33. Id. (citing Compl., supra note 4,
33, 35, 36).
34. Id.
35. Id.
36. President Abraham Lincoln, Lecture on Discoveries, Inventions, and
Improvements (Feb. 22, 1860).

https://via.library.depaul.edu/jatip/vol20/iss2/9
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progress.37 Our patent system has been designed to achieve this
purpose by encouraging invention and disclosure.3" "The patent
laws promote this progress by offering a right of exclusion for a
limited period as an incentive to inventors to risk the often
enormous costs in terms of time, research, and development."39
Patents act as an important incentive for commercial enterprises to
invest in the production and application of knowledge.4"
This system functions by the government granting inventors a
unique property right to "exclude others from making, using, or
selling the invention ...beginning on the date on which the patent
issues and ending twenty years from the date on which the
application for the patent was filed."41 This right of exclusion is
the inventor's "reward for inventions."42 In return for this
exclusionary right, the inventor is obligated to disclose a
substantial utility of the genetic material, that is, to teach others
how to use the invention in a novel way.43 Disclosure of the
invention to the public serves two functions: (1) enabling other
inventors to learn about the patented invention and to develop
improvements; and (2) permitting the public to practice the

37. Although the stimulation of scientific progress is a significant rationale
underlying the patent system, there are numerous other rationales in addition.
See, e.g., JANICE M. MUELLER, PATENT LAW (3d ed, Aspen Publishers, Inc.
2009) (describing the "monopoly profits incentive" rationale, the "reward for
services rendered" theory and the "exchange for secrets" rationale).
38. See Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470, 480-481 (1974).
39. Id. at 480.
40. See NUFFIELD COUNCIL ON BIOETHICS, supra note 21, ch.2, 2.6 at 13.
41. 35 U.S.C. § 154; see also, Kane, supra note 23 (stating that an important,
yet often misunderstood, distinction is that a patent does not confer ownership
rights, it confers property rights).
42. Kewanee, 416 U.S. 470, 480 (citing Universal Oil Co. v. Globe Co., 322
U.S. 471, 484 (1944).
43. See Utility Examination Guidelines, 66 Fed. Reg. 1092, cmt. 7 at 1094
(Jan. 5, 2001) (hereinafter USPTO Guidelines); see also 35 U.S.C. § 112, 1
(2006) which requires:
The specification shall contain a written description of the
invention, and of the manner and process of making and using
it, in such full, clear, concise, an d exact terms as to enable
any person skilled in the art to which it pertains, or with which
it is most nearly connected, to make and use the same ....
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invention once the patent expires." As a result, the patent system
represents "a carefully crafted bargain that encourages both the
creation and the public disclosure of new and useful advances in
technology, in return for an exclusive monopoly for a limited
period of time. 45
Patent law is rooted in the U.S. Constitution, Article I, section 8,
clause 8, which reads: "Congress shall have the power ....

[t]o

promote the Progress of Science and useful Arts, by securing for
limited Times to Authors and Inventors the exclusive Right to their
respective Writings and Discoveries."46
Pursuant to this
constitutional provision, Congress enacted the first federal patent
statute in 1790. 47 Our current federal patent law is codified in the
1952 Patent Act, which provides that "[w]hoever invents or
discovers any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement
thereof, may obtain a patent therefor, subject to the conditions and
48
requirements of this title.
The United States Patent and Trademark Office ("USPTO") is
the "administrative agency with patent examination and grant
authority. '49 Before a patent is granted, a patent application
undergoes substantial examination by the USPTO.5
It is their
responsibility to enforce the requirements set forth by Congress in
the Patent Act and to assure that ideas in the public domain remain
there for the free use of the public.5' The threshold issue in the
examination process is the determination of patentable subject

44.
45.
46.
47.

Id.
Pfaffv. Wells Elec. Inc., 525 U.S. 55, 63 (1998).
U.S. CONST. art. I, § 8, cl. 8.
See Patent Act of 1790, ch. 7, 1 Stat. 109; see also DONALD S. CHISUM ET

AL., PRINCIPLES OF PATENT LAW: CASES AND MATERIALS 18 (2d ed. 2001);

Ladas & Parry LLP, A Brief History of the Patent Law of the United States,
http://www.ladas.com/PatentsiUSPatentHistory.html (last visited Feb. 10,
2010).
48. 35 U.S.C. § 101 (2006).
49. Qin Shi, Patent System Meets New Sciences: Is the Law Responsive to
Changing Technologies and Industries?, 61 N.Y.U. ANN. SURV. AM. L. 317,
318 (2005).
50. NUFFIELD COUNCIL ON BIOETHICS, supra note 21, ch.2, box 2.1 at 11.

51. See Thomas & Betts Corp v. Panduit Corp., 138 F.3d 277, 284 (7th Cir.

1997).
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matter, defined as eligibility. 2 The Patent Act defines patenteligible subject matter as "any new and useful process, machine,
manufacture, or composition of matter or any new and useful
improvement thereof."53 Second, the inventor must establish that
his invention is new, useful, and nonobvious 4 Lastly, the
specification of the patent application must adequately describe the
invention and clearly teach others how to make and use the
invention.5 The Patent Act also specifies that the enforceable life
of a patent is limited to twenty years after the filing date of the
patent application.56 At the end of this term, the patent expires and
the invention enters the public domain to become free for all to
make and use. 7
The United States' status as a world leader in scientific
discovery and development58 is often credited to its openness to
granting patents. 9 Naturally occurring substances have been held
to be patentable since a 1912 decision, which upheld a patent on
adrenaline provided that it was isolated from its natural source.6"
In 1980, the Supreme Court affirmed the patentability to include
both living organisms and biological materials by affirming a
patent on a genetically engineered bacterium.6' In more recent
years, Harvard University has been granted multiple patents on the
"oncomouse," a mouse that had been genetically engineered to be

52. See State St. Bank & Trust Co. v. Signature Fin. Group, Inc., 149 F.3d
1368, 1372 (Fed. Cir. 1998) (stating that subject matter eligibility is the "first
door which must be opened on the difficult path to patentability ....).
53. 35 U.S.C.§ 101. However, the Supreme Court has held that patent
protection is not available for "laws of nature, natural phenomena, and abstract
ideas." See, e.g., Diamond v. Diehr, 450 U.S. 175, 185 (1981).
54. See 35 U.S.C. §§ 102, 101, 103 (requiring novelty, utility, and

nonobviousness respectively).
55. 35 U.S.C. § 112,

1 (2006).

56. 35 U.S.C. § 154(a)(2) (2006); see also MUELLER, supra note 37, at 568.
57. See MUELLER, supra note 37, at 27.
58. See Bio Letter, supra note 2, at 11-12.
59. Josephine Johnston & Angele A. Wasunna, Patents, Biomedical
Research, and Treatments: Examining Concerns, Canvassing Solutions,
HASTINGS CTR.REP., (Jan.-Feb. 2007), at S9.
60. Id. (citing Parke-Davis & Co. v. H.K. Mulford & Co., 196 F. 496 (2d Cir.
1912)).
61. Id. (citing Chakrabarty,447 U.S. 303 (1980)).
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susceptible to cancer.6 2 Thus, the courts have consistently
interpreted the patent clause of the Constitution broadly and have
not refrained from granting patent rights on higher life forms,
provided that they are new and useful contribution to the public
domain.
C. Gene Patents: The Intersectionof Genomics and PatentLaw
"The biotechnology industry pinpoints its modem origin to two
seminal events that occurred in 1980: The passage of the BayhDole Act and the landmark U.S. Supreme Court decision of
63 First, the Bayh-Dole Act' enabled
Diamond v. Chakrabarty."
universities, research institutions, and other non-profit federal
contractors and grantees to seek patent protection for their
inventions made with government funding and retain the
royalties.65 Second, Chakrabarty was a landmark U.S. Supreme
Court decision that "opened the door for the patenting of key
biotechnology inventions, including biological materials and living
organisms."66 These two events, which both occurred in 1980,
triggered a cascade of subsequent advancements in patent law.
Nearly six months after the Supreme Court's decision in
Chakrabarty,the first patent on a recombinant DNA method was
granted in December 1980.67 Subsequently, in 1982, the USPTO
granted the University of California a patent on the gene for
insulin,6" and for almost three decades, biotechnology companies
62. Johnston, supra note 59, at S9 (discussing the oncomouse patents which
were granted to Harvard University in 1988 and 1992).
63. Bio Letter, supra note 2, at 2.
64. Bayh-Dole Act, 35 U.S.C. § 202 (2006).
65. NUFFIELD COUNCIL ON BIOETHICS, supra note 21, ch. 1, 1.6 at 4.
66. Bio Letter, supra note 2, at 2.
67. "Recombinant DNA [refers to] [a]rtificial DNA made by splicing DNA
strands from different organisms. It is used for many purposes, such as
replicating DNA for research, producing important proteins, and devising gene
therapies." ROBERT COOK-DEEGAN, FROM BIRTH TO DEATH AND BENCH TO
CLINIC: THE HASTINGS CENTER BIOETHICS BRIEFING BOOK FOR JOURNALISTS,

POLICYMAKERS, AND CAMPAIGNS,

70 (Mary Crowley ed., Garrison, NY: The

Hastings Center, 2008), availableat http://www.thehastingscenter.org/
uploadedFiles/Publications/BriefingBook/gene%20patents%20chapter.pdf.
68. Id. This recombinant human insulin also became the first biotech therapy
to earn FDA approval in 1982. BIOTECHNOLOGY INDUSTRY ORGANIZATION,
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have "used patents to secure commercial protection, and count on
it in a critical fashion to guide their business development and
investment decisions."69 Currently, there are 3,000-5,000 U.S.
patents on human genes and 47,000 on inventions involving
genetic material."0
The patent-eligibility of isolated and purified DNA molecules
has never been directly addressed by the Supreme Court; however,
lower appellate courts have repeatedly granted patents on purified
and isolated DNA molecules." The USPTO clearly states that, a
nucleic acid, like any other type of chemical compound, is
patentable if it is new, useful, and not obvious.7 A human gene as
it occurs in nature cannot be patented. The USPTO may grant
patents on DNA molecules or genetic material but have set forth
strict guidelines on patents. These requirements state that the
nucleic acid must be new in order to be eligible for receiving a
THE GUIDE TO BIOTECHNOLOGY (Roxanna Guilford-Blake & Debbie Stricland
eds., 2008), availableat http://bio.org/speeches/pubs/er/BiotechGuide2008.pdf.
69. Jeffrey P. Kushan, Prepared Statement on behalf of the Biotechnology
Industry Organization on "Stifling or Stimulating - The Role of Gene Patents in
Research and Genetic Testing" at 15 (Oct. 30, 2007), available at
http://www.bio.org/ip/action/20071030.pdf.
70. COOK-DEEGAN, supra note 67, at 69.
71. BIO Brief supra note 11, at 14; see also Amgen, Inc. v. Chugai Pharm.
Co., Ltd., 927 F.2d 1200, 1206 (Fed. Cir. 1991), cert. denied, 502 U.S. 856
(affirming patentability of claims directed to, inter alia, a "purified and isolated
DNA sequence consisting essentially of a DNA sequence encoding human
erythropoietin."); Fiers v. Revel, 984 F.2d 1164 (Fed. Cir. 1993) (affirming
priority of invention to party that met enablement requirement of §112, 1 for a
claim directed to a "DNA which consists essentially of a DNA which codes for
a human fibroblast interferon-beta polypeptide").
72. The USPTO has stated the following:
"An isolated and purified DNA molecule that has the same
sequence as a naturally occurring gene is eligible for a patent
because (1) an excised gene is eligible for a patent as a
composition of matter or as an article of manufacture because
that DNA molecule does not occur in that isolated form in
nature, or (2) synthetic DNA preparations are eligible for
patents because their purified state is different from the
naturally occurring compound."
USPTO Guidelines, supra note 43, at 1093.
73. Science, State, Justice, Commerce, and Related Agencies Appropriations
Act of 2006, § 623, Pub. L. No. 109-108, 119 Stat. 2290, 2342.
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patent, meaning the claimed molecule must be distinct from any
nucleotide sequence that has been reported in literature, cannot be
already known from earlier experimental work, and must be
limited to a specific nucleotide sequence that does not occur in that
form in nature.74 Additionally, the applicant must identify a utility
that (i) is specific to the claimed invention, and (ii) must be
substantial, in that it provides "real world value.""
III. SUBJECT OPINION

A.

The History of Myriad's Patents

In 1990, a group of researchers discovered that a gene, BRCA1,
correlated with an increased risk of breast and/or ovarian cancer."
Subsequently, another research team sequenced the precise
BRCA1 gene, and these two groups formed Myriad Genetics, a
Salt Lake City-based for-profit company that subsequently
sequenced a second gene, BRCA2.77 Certain mutations in these
two genes (collectively referred to as BRCA1/2) confer an
increased risk of inherited breast and/or ovarian cancer."8 With
this knowledge, Myriad Genetics developed a diagnostic test,
BRACAnalysis, to detect the presence of these mutations and
assist in a woman's decision in preventative precautions.79
As the first discoverer of this genetic correlation, Myriad

74. Kushan, supra note 69, at 9.
75. "Real world value" means that "one skilled in the art can use a claimed
discovery in a manner which provides some immediate benefit to the public."
Id.(citing In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005)).
76. Order Denying Motion to Dismiss, supra note 12, at 25; Compl., supra
note 4, 42.
42-43.
77. Compl., supranote 4,
78. Compl., supra note 4, 44.
79. See Bob Carlson, Gene Patents on the Line, BIOTECHNOLOGY
HEALTHCARE, Oct. 2009, 8-10; availableat http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC2799099/pdf/bthO6_4pOO8.pdf ("Together with a family history
and other medical information, a BRACAnalysis report can help a medical
geneticist or a genetic counselor provide critical guidance about prevention and
treatment options to a patient who may be considering a prophylactic
mastectomy or oophorectomy.").
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Genetics secured the patents to the genes, their mutations, and the
screening tests in the mid-1990's. Myriad's success in sequencing
the BRCA genes has resulted in an invaluable tool for preventative
medicine. Myriad currently offers two diagnostic tests: (1) the
Comprehensive BRACAnalysis Test, which costs approximately
$3,000; and (2) the BRACAnalysis Rearrangement Test, which
As the patent-holder, Myriad
costs approximately $600.80
Genetics has the right to preclude other companies from
performing the BRCAanalysis test until their patent term expires.
Myriad has not licensed out their diagnostic tests to other
laboratories, thus, the only available option in the United States for
a woman seeking testing of her BRCA1/2 genes is for her to utilize
Myriad's tests.81 Myriad Genetics has notoriously enforced their
patent rights, thus, generating increasing concern regarding the
implications the BRCA patents have on access to health care and
research.
B.

The Complaint

The complaint filed in 2009, Association for Molecular
Pathology, et al. v. United States Patent and Trademark Office,82
challenged the constitutionality and the validity of a series of
patents on two human genes, BRCA183 and BRCA2, that are
closely connected with breast and ovarian cancer.84 The suit was
directed against Myriad Genetics85 the exclusive licensee of the

80. Order Denying Motion to Dismiss, supra note 12, at 36; Compl., supra
note 4,
92, 94.
81. Order Denying Motion to Dismiss, supra note 12, at 36; Compl., supra

note 4,

84, 90.

82. Compl., supra note 4.
83. The term "BRCAI" refers to a particular fragment of DNA found on
chromosome 17 that relates to a person's predisposition to develop breast and
ovarian cancer. This particular fragment of DNA is referred to as "the BRCA1
gene." PL. 's Memo, supranote 19, at 2.
84. Compl., supra note 4, 2.
85. Myriad Genetics is a for-profit corporation located in Salt Lake City,
Utah. Myriad is a co-owner of one of the patents-in-suit and holds the exclusive
licenses for the remaining ones. It is currently the sole provider of full
sequencing of the BRCA genes in the United States. Order Denying Motion to
Dismiss, supranote 12, at 22-23 (citing Compl., supra note 4, 28.).
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patents at issue, as well as directors of the University of Utah
Research Foundation (UURF)86 and, in an unusual move, the
United States Patent and Trademark Office (USPTO)."7
The complaint, organized and filed by the American Civil
Liberties Union (ACLU) and the Public Patent Foundation
(PUBPAT),"8 was filed on behalf of an unusually large group of
plaintiffs (hereinafter ACLU) including four scientific
organizations representing more than 150,000 geneticists,
pathologists, and laboratory professionals, individual researchers,
breast cancer and women's health groups, genetic counselors, and
individual women.8" Since the filing of this complaint, the ACLU
has withdrawn itself from the class of plaintiffs, but remains as
their legal representative in the lawsuit.9"
This suit is a declaratory judgment action that requests the court
to invalidate the specific patents at issue, as well as to declare the
PTO's entire patent-granting policy unconstitutional. In filing this
complaint, the ACLU challenged the legality and constitutionality
of patents over human genetic material on the basis of (1) 35
86. "The UURF is a not-for-profit corporation located in Salt Lake City,
Utah, that the Plaintiffs allege is operated, supervised, and/or controlled by the
University of Utah. The UURF is an owner or part-owner of all of the patentsin-suit." Id. at 23 (citing Compl., supra note 4, 29).
87. "The USPTO is an agency of the Commerce Department of the United
States. The Plaintiffs assert only their claims for constitutional violations
against the USPTO." Id, at 22 (citing Compl., supra note 4, 27). The USPTO
being named as a defendant is an unusual twist as the PTO "has never been a
party to a lawsuit in which the constitutionality of patents issued by the USPTO
were brought into question." Jake Meyer, Motion to Dismiss Denied in Breast
Cancer Case: The USPTO is a Defendant in a Case Challenging the
Constitutionality of Patents Granted by the USPTO, Nov. 9, 2009,
http://blogs.kentlaw.edu/islat/2009/ 1/motion-to-dismiss-denied-in-breastcancer-case-the-uspto-is-a-defendant-in-a-case-challenging-the-co.html.
By
naming the USPTO as a defendant, the ACLU intends to invalidate the entire
practice of granting patents on human genes by challenging the Patent Office's
formal written policy which provides that naturally occurring genes can be
patented if they are 'isolated from their natural state and purified."' Compl.,
supra note 4, 50.
88. A not-for-profit patent reform organization affiliated with the Benjamin
N. Cardozo School of Law in New York.
89. Woollacott, supra note 9.
90. This suit is the first patent case in the ACLU's nearly ninety-year history.
See Brendan L. Smith, Wrangling Genes, ABA. J., July 2009, at 95.
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U.S.C. § 101 of the patent statute,9 1 (2) Article I, Section 8, Clause
8 (the "IP Clause") of the U.S. Constitution,92 and (3) the First
And Fourteenth Amendments to the U.S. Constitution. 13 Two
main causes of action are raised in this lawsuit.9 4 First, the ACLU
alleged that "human genes are products of nature, laws of nature
and/or natural phenomena" and therefore are invalid under both
the IP Clause and the Patent Act. " Second, it alleged that gene
patents "represent patents on abstract ideas or basic human
knowledge and/or thought and therefore are unconstitutional under
the First and Fourteenth Amendments to the U.S. Constitution. 9 6
The patent claims being challenged by the Plaintiffs are divided
into four groups: (1) claims to isolated, non-mutated forms of
BRCA1 and BRCA2; (2) claims to isolated forms of BRCA1 and
BRCA2 that contain mutations that may or may not have any
correlation with an increased risk of breast and ovarian cancer; (3)
claims directed to any method of analyzing an individual's
BRCA1 gene to determine whether the individual's gene contains
an inherited mutation; and (4) claims covering comparison of a
patients' BRCA1 and BRCA2 gene sequences to determine
whether there are differences that would indicate a genetic

91. 35 U.S.C. § 101. The statutory claims brought under the Patent Act
allege that Myriad's patents are invalid for failing to meet the statutory
requirements for issuance of a patent.
92. Constitutional clause that empowers Congress to "promote the Progress
of Science and useful Arts, by securing for limited Times to Authors and
Inventors the exclusive Right to their respective Writings and Discoveries."
U.S. CONST.art. 1, § 8, cl. 8.
93. Compl., supra note 4,
102-103; TT 52,54; Order Denying Motion to
Dismiss, supra note 12, at 35; see also Mark Fass, 'Law of Nature' or
'Invention'? Court Mulls Patentability of Genes, N.Y.L.J., Feb. 3, 2010
(quoting Assistant U.S. Attorney Ross Eric Morrison, who represents the Patent
Office, noting that "[t]here is 'not a single case' in which a court 'has
considered, let alone upheld,' a constitutional claim in a patent case").
94. Compl., supra note 4, 7 102-103 at 29.
95. Id. 52 at 19.
96. The First Amendment states that "Congress shall make no law respecting
an establishment of religion, or prohibiting the free exercise thereof, or
abridging the freedom of speech, or of the press...". See U.S. CONST. amend I.
The Due Process Clause of the Fourteenth Amendment applies the First
Amendment to each state, including any local government. See U.S. CONST.
amend XIV.
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predisposition to cancer. 7
C.

The District Court'sDenial of the Defendants' Motion to
Dismiss

Following the initial filing of the complaint, defendants USPTO
and Myriad Genetics each filed independent motions to dismiss the
case 98 on a variety of grounds including lack of personal and
subject matter jurisdiction, lack of standing, and failure to state a
claim. 99 On November 1, 2009, the Southern District of New
York found the case to have legitimate constitutional grounds and
denied all of the Defendants' motions to dismiss.' 0 Judge Sweet
recognized the importance of this case, stating:
The widespread use of gene sequence information
as the foundation for biomedical research means
that resolution of these issues will have far-reaching
implications, not only for gene-based health care
and the health of millions of women facing the
specter of breast cancer, but also for the future
course of biomedical research. '

97. OrderDenying Motion to Dismiss, supra note 12, at 33-34.
98. All motions were filed on July 13, 2009; see http://docs.justia.com/
cases/federal/district-courts/new-york/nysdce/1:2009cv04515/345544/25/
(USPTO's motion to dismiss); http://docs.justia.com/cases/federal/districtcourts/new-york/nysdce/1:2009cv04515/345544/27/ (Myriad's motion
to dismiss).
99. The majority of the jurisdictional issues, which are outside the scope of
this article, were grounded in the fact that none of the plaintiffs had actually
been sued for infringement by Myriad. These motions included arguments that
the Court lacks subject matter jurisdiction over Plaintiffs' claims against the
PTO, the Plaintiffs lack standing to bring this declaratory judgment action, the
Court lacks personal jurisdiction over the UURF Directors, and that the
Plaintiffs failed to sufficiently plead a claim. OrderDenying Motion to Dismiss,
supra note 12, at 37 - 38.
100. The district court denied all of the USPTO's procedural objections
finding that (1) the plaintiffs had standing to sue the USPTO for constitutional
violations; (2) the plaintiffs have established standing to sue Myriad and the
Directors; and (3) jurisdiction existed over the directors. Id. at 34.

101. Id. at 2.
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Judge Sweet allowed the case to continue forward on the ground
stating "Plaintiffs have pled sufficient factual allegations" to
survive Defendants' motion to dismiss. 2 On a motion to dismiss,
"the question before the court 'is not whether a plaintiff will
ultimately prevail but whether the claimant is entitled to offer
evidence to support the claims."'" °3 The opinion found that "[t]he
facts alleged in the Complaint are plausible, specific, and form a
sufficient basis for Plaintiff s legal arguments."'"
D. CurrentlyPending Motions
While the Defendants' motions to dismiss were still pending in
the district court, Plaintiffs moved for summary judgment on the
substantive issue in August 2009. This motion was stayed,
pending resolution of Defendants' motion to dismiss. 5 Myriad
defendants, Myriad Genetics and UURF, filed a response in
opposition to the motion for summary judgment, as well as filing
their own motion for summary judgment on the grounds that all of
the patent claims at issue cover patent-eligible subject matter. The
USPTO filed a motion for judgment on the pleadings on December
24, 2009. On February 2, 2010, Judge Sweet heard oral arguments
from both sides. "Both sides suggested there is little, if any,
disagreement over the facts, so the case seems likely to be decided
06
without a trial."'

IV. ANALYSIS

A.

IsolatedHuman-DNA is Patent-EligibleSubject Matter.

The classes of subject matter that are eligible to receive patents
are defined by section 101 of the Patent Act which states:

102. Id. at 82.
103. Id.at 81-82 (citing Villager Pond, Inc. v. Town of Darien, 56 F.3d 375,
378 (2d Cir. 1995)).
104. Id. at84.
105. OrderDenying Motion to Dismiss, supra note 12, at 4.
106. Fass, supra note 93, at 1.
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Whoever invents or discovers any new and useful
process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof,
may obtain a patent thereof, subject to the
conditions and requirements of this title.' 7
Section 101 is not without limits. Laws of nature, natural
phenomena and abstract ideas are excluded from patent
protection.0 8 However, the Supreme Court has interpreted these
exclusions narrowly, for "Congress intended statutory subject
matter 'to include anything under the sun that is made by man. "'l09
The ACLU alleged that human genes, as well as the information
encoded in the genetic sequences, are products of nature; thus,
they claim unpatentable subject matter."' The ACLU claimed that
Myriad Genetics merely located these genes and "described their
informational content as it exists and functions in nature." This
argument is not persuasive. Although patents generally may not
be granted for "products of nature," it is well-established that
law of nature in a new and useful way may well be
application of a.
Furthermore, human
deserving of patent protection."'
manipulation of a naturally occurring organism that results in a
non-naturally occurring organism may be the subject of a patent if
107. 35 U.S.C. § 101.
108. Laws of nature, natural phenomena and abstract ideas are judiciallycreated exceptions that have been read into the statutory classes of patenteligible subject matter. See, e.g., Chakrabarty,447 U.S. at 309 (stating that
Einstein could not have "patent[ed] his celebrated law that E-mc2;nor could
Newton have patented the law of gravity"); see also Benson, 409 U.S. at 67, 93
(stating that "[p]henomena of nature, though just discovered, mental processes,
and abstract intellectual concepts are .... the basic tools of scientifics and
technological work").
109. Diehr, 450 U.S. at 182 (citing S. Rep. No. 1979, 82d Cong., 2d Sess., 5
(1952); H.R. Rep. No. 1923, 82d Cong., Sec. 2d Sess., 6 (1952)).
110. The ACLU alleges that gene patenting "violates long established legal
principles that prohibit the patenting of laws of nature, products of nature, and
abstract ideas."
111. See 35 U.S.C. § 102; see also Funk Bros. Seed Co. v. Kalo Inoculant
Co., 333 U.S. 127, 130 (1948) ("He who discovers a hitherto unknown
phenomenon of nature has no claim to a monopoly of it which the law
recognizes. If there is to be invention from such a discovery, it must come from
the application of the law of nature to a new and useful end") (emphasis added).
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it meets the other statutory criteria for patentability.112
Myriad's patents claim genes that are qualitatively different than
those that exist in nature. These claims are directed to "isolated
and purified genes" that have been "isolated from their natural
state and processed through purifying steps that separate the gene
'
from other molecules naturally associated with it."113
As a result,
despite the ACLU's argument, the natural occurrence of genes in
nature is not a bar to patentability.
1. A Long History ofJudicialPrecedent:Isolated and Purified
Products of Nature
Judicial precedent also clearly affirms the USPTO's current
policy that "discoveries from nature which are transformed into
new and useful products are eligible for patents." '14 For almost a
century, the judicial system has upheld patents on isolated
substances that "differ in kind from their natural counterparts," on
the basis that the process of isolation and purification results in a
compound no longer in its natural form. 15 Based on these rulings,
the USPTO has issued thousands of gene patents, reasoning that in
these cases, human intervention generates isolated DNA molecules
no longer in their natural form.1 6 As a result, when isolated and
purified, the BRCA1 gene is eligible for a patent either as a
composition of matter, or as an article or manufacture, because it
17
does not exist in that isolated form in nature.'
Courts have repeatedly recognized a difference between a mere
product of nature and an "isolated and purified" product of nature,
112. Kane, supra note 23, at 733.
113. USPTO Guidelines, supra note 43, at 1093.
114. Id. at 1094.
115. BIO Brief supra note 11, at 1 (citing Parke-Davis, 189 F. 95 (S.D.N.Y.
1911)) ("jurisprudence originating in this Court has recognized the patenteligibility of isolated substances that differ in kind, and not merely in degree of
purity, from their natural counterparts").
116. See Kane, supra note 23, at 738; see also Funk Bros., 333 U.S. at 130
(stating "if something naturally occurring in nature is substantially modified in a
novel way via human interaction the modified result may be patentable").
117. See USPTO Guidelines, supranote 43, cmt. 2, at 1092 (confirming that
"[p]atenting compositions or compounds isolated from nature follows wellestablished principles and is not a new practice").
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holding only the latter to be patentable. In 1873, the PTO first
granted a patent on a purified form of a natural product, yeast,
when Louis Pasteur was awarded a patent claiming "[y]east, free
from organic germs of disease, as an article of manufacture.""' 8
Subsequently, in 1911, Parke-Davis & Co. v. H.K. Mulford Co,
became the first case to articulate the idea that isolation of a
product from its natural surroundings constituted human
intervention sufficient to transform a natural compound into a new
and useful product that was now worthy of patent-eligibility." 9
The Parke-Davis patent was directed towards the purified form of
adrenaline, a naturally occurring horomone, and was upheld on the
basis that the inventor was "the first to make it available for any
use."' 20 The court found that as a result of the inventor, adrenaline
was identified, isolated, and purified and now "became for every
practical purpose a new thing commercially and therapeutically."''
The 1958 case, Merck & Co. v. Olin Mathieson Chem. Corp.,
further affirmed the patenting of a product of nature on the basis
that the isolation and purification process resulted in a new
substance, whose utility entitled it to patent protection.'22 The
court in Merck upheld a patent on naturally occurring vitamin B12
compositions, reasoning that "the step from complete uselessness

118. Chakrabarty, 447 U.S. at 314 n.9 (noting that in 1873, Louis Pasteur
obtained U.S. Pat. No. 141,072, which contained the following claim: "[Y]east,
free from organic germs of disease, as an article of manufacture").
119. Parke-Davis, 189 F. at 103 (L. Hand, J.) (confirming the legality of
issuing patents on natural compounds such as adrenaline by stating "even if it
were merely an extracted product without change, there is no rule that such
products are not patentable").
120. Id. The court reasoned this was "a good ground for a patent" since
adrenaline, like many naturally occurring compounds, could not be used without
first being isolated and purified. Id.
121. Id. The patent in suit claimed adrenaline in its isolated and purified
substance possessing the herein-described physiological
form: "[a]
characteristics and reactions of the suprarenal glands in a stable and
concentrated form, and practically free from inert and associated gland-tissue."
Parke-Davis, 196 F. 496, 497 (emphasis added); see also USPTO Guidelines,
supra note 43, cmt. 2, at 1093.
122. Merck & Co v. Olin Mathieson Chem. Corp., 253 F.2d 156, 164 (4th
Cir. 1958) ("The new products are not the same as the old, but new and useful
compositions entitled to the protection of the patent").
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to great and perfected utility is a long one.' ' 1 3 The court noted that
the vitamin B12 compositions as found in nature had no utility,
"therapeutically
or commercially,
until
converted
into
compositions comparable to the patented products.' 24
The 1970 case, In re Bergstrom, held that pure PGE 2 and PGE 3
were patent-eligible subject matter once again on the grounds that
the claimed compounds did not exist in nature in pure form.'25
Even more recently, the 2003 case Schering Corp v. Geneva
Pharmaceuticals,found that there was no per se bar to patenting a
metabolite, a naturally occurring product produced during normal
metabolism of a known compound, if the metabolite was clearly
1 26
claimed in a non-naturally occurring form.
2.

The "IsolatedandPurified" Doctrineand DNA.

The series of cases described in the preceeding section illustrate
that the natural occurrence of a product in nature is not a bar to
patentability. This principle is also directly applicable to gene
patents claiming DNA molecules. 127 The PTO, who has granted
thousands of gene patents, treats genes as it does any other
chemical compound and determines isolated and purified genes to
be eligible for patents as compositions of matter. 128 The validity
of these patents is founded on the basis that isolated and purified
genes are qualitatively different than those that exist in nature
when the claims are directed to DNA molecules that (1) do not
123. Id.

124. Id. at 161.
125. In re Bergstrom, 427 F.2d 1394, 1397 (C.C.P.A. 1970).
126. Schering Corp. v. Geneva Pharm., Inc., 339 F.3d 1373, 1381 (Fed. Cir.

2003) ("the metabolite may be claimed in its pure and isolated form ... ").
127. USPTO Guidelines, supra note 43, cmt. 2, at 1093 ("Like other

chemical compounds, DNA molecules are eligible for patents when isolated
from their natural state and purified"); see also Amgen Inc. v. Chugai Pharm.
Co., 927 F.2d 1200, 1206 (Fed. Cir. 1991) ("A gene is a chemical compound,

albeit a complex one, and it is well established in our law that conception of a
chemical compound requires that the inventor be able to define it so as to
distinguish it from other materials, and to describe how to obtain it.") (emphasis
added).
128. See generally W. Edward Ramage, Challenging the Patentability of
Genes, availableat http://www.abanet.org/litigation/committees/intellectual/

roundtables/0 11 0outline.pdf.

Published by Digital Commons@DePaul, 2016

23

DePaul Journal of Art, Technology & Intellectual Property Law, Vol. 20, Iss. 2 [2016], Art. 9

496

DEPAUL J ART, TECH. & IP LAW

[Vol. XX:2

occur in that isolated form in nature; and (2) are of a purified state
29
that is different from the naturally occurring compound.
Despite this well-established history, the ACLU maintains that
in the present case, the 'isolation' of DNA means nothing more
than removing a gene from the body and separating it from the
surrounding cellular material.13° However, the process is not
nearly as simplistic as the ACLU portrays. Myriad Genetics has
"transformed a deleterious gene buried among over 25,000 known
genes in the patient's chromosomes to make it detectable using
modem diagnostic methods and machinery..".3 Brian Poissant, the
lead attorney for Myriad Genetics in the present suit, analogizes
Myriad Genetic's innovation as "if the DNA from a single human
nucleus were stretched out, it would extend to the moon, and that
Myriad had located a single gene within that 25,000-mile
32
strand."'1
Nevertheless, the ACLU alleges that an "'isolated and purified'
human gene performs the exact same function as a non-isolated
and purified human gene in a person's body... [and] [r]emoving a
product of nature from its natural location does not make it any
less a product of nature."' 33 This argument lacks merit. Myriad's
patents do not claim the BRCA genes as they occur in nature. It is
the terms "isolated" and "purified" that distinguishes the claimed
molecules from anything that exists in nature.'34 The isolation
process removes the DNA from other cellular substances and
creates discrete molecules that can be manipulated by molecular
biological techniques.' 35
The process of "isolation and
3
'
6
purification"
imparts isolated DNA molecules with new
129. USPTO Guidelines, supra note 43, at 1093.
130. Pl.'s Memo, supra note 19, at 3-4.
131. Myriad Memo, supra note 1, at 8.
132. Fass, supra note 93, at 1.
133. Compl., supra note 4, at 19 52.
134. See USPTO Guidelines, supra note 43, at 1092.
135. BIO Brief supra note 11, at 15; see also USPTO Guidelines, supra note
43, at 1093 (stating that the genetic sequences have been "isolated from their
natural state and processed through purifying steps that separate the gene from
other molecules naturally associated with it).
136. "Isolation and purification" refers to the process scientists undergo to
identify any particular sequence or sequence fragment of human DNA. Debra
Greenfield, Intangible or Embodied Information: The Non-Statutory Nature of
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chemical, structural, and functional properties, thus creating a
fundamentally new product.137
The patents at issue are analogous to the patent upheld in
Diamond v. Chakrabarty, where the Supreme Court upheld a
patent on the grounds that human intervention generated a
genetically engineered bacterium possessing a property that no
naturally-occurring bacterium possessed: the ability to break down
multiple components of crude oil.'3 8 In the present case, as the
result of human intervention, isolated and purified genes possess
new properties that their naturally-occurring counterparts do not
have. For example, "unlike native DNA, the isolated form can be
used as a probe, a diagnostic tool that a molecular biologist uses to
target and bind to a particular portion of DNA, allowing it to be
detectable using laboratory machinery."' 39 However, native DNA
cannot be used as a probe because it lacks the chemical, structural,
or functional properties of the isolated and purified form of the
DNA. 140 The utility that arises in the isolated form of the DNA
molecules is based on their ability to target and interact with other
DNA molecules, which is a function of their own individual
structure and chemistry. 4 1 Just like the bacterium in Chakrabarty,
the isolation and purification of DNA results in genes holding
"markedly different characteristics from any found in nature and
1 42
one having the potential for significant utility.'
Furthermore, it is justifiable to grant gene patents to whoever
transformed them into something more useful than made in nature;
this is exactly what happened in the present case against gene
patents. 143 It is well-established that patents may be granted on a
Human Genetic Material, 25 SANTA CLARA COMPUTER & HIGH TECH. L.J. 467,
482 (2009) (citing Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200 (Fed. Cir.
1991)).
137. Myriad Memo, supranote 1, at 8.
138. Chakrabarty,447 U.S. at 305.
139. Myriad Memo, supra note 1, at 8.
140. Id.
141. Id. at 33.
142. Pl. 's Memo supra note 19 (citing Chakrabarty,447 U.S. at 310).
143. Hans Sauer, Associate General Counsel for Intellectual Property, BIO,
Kojo Nnamdi Show; WAMU 88.5 FM; American University Radio; Thursday,
June 4, 2009 at 1:06 p.m., available at http://thekojonnamdishow.org/shows/
2009-06-04/patenting-genes; see Declaration of Joseph Straus at 11, Ass'n for
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discovery "natural phenomenon" when an invention arises from its
application to a new and useful end.'44 In the present case, Myriad
Genetics has described a "specific, substantial, and credible
utility" for the claimed isolated and purified BRCAl/2 genes, or in
other words they have disclosed how to use the purified BRCA
genes isolated from their natural state.'45 Myriad's disclosed
invention comes from the utility of the genes once they have been
removed from their location in nature. Myriad Genetics has been
the first to find a specific and substantial use for these genetic
sequences and is the first researcher to have transformed them into
a new thing commercially and therapeutically. As a result of their
investment and innovative research, Myriad Genetics discovered
and isolated genes involved in human disease and has developed
and commercialized important medical diagnostic tools. 146
Currently, Myriad Genetics offers an innovative and beneficial
service to women via the diagnostic tests that determine a
woman's predisposition to breast and ovarian cancer. 47 As a
result, society benefits from Myriad's investment.

Molecular Pathology v. USPTO, No. 09-4515 (S.D.N.Y. filed May 12, 2009),
available
at
http://docs.justia.com!cases/federal/district-courts/newyork/nysdce/1:2009cv04515/345544/173 (justifying patentability "where the

inventor is the first to identify a gene and its useful function, to isolate and clone
the nucleic acid of the gene and thereby make synthetic copies of the nucleic
acid that are available for use in diagnosis or therapy").
144. Funk Bros., 333 U.S. at 130; In order for a purified and isolated gene

composition to be patentable, it must additionally satisfy the Patent's Act
"utility" requirement, meaning the application must disclose a "specific,
substantial, and credible utility." USPTO Guidelines, supra note 43, at 1093.

145. Id.
146. Myriad Memo, supra note 1, at 1 ("Myriad has performed over 400,000

BRACAnalysis tests for patients in all fifty states.

Over 40,000 healthcare

providers have used the test").
147. See Brief for Myriad Genetics Inc. as Amici Curiae Supporting
Appellants, PrometheusLaboratories,Inc. v. Mayo CollaborativeServices, 581
F.3d 1336 (2009) (No. 2008-1403), 2009 WL 462604 ("Myriad's currently

marketed personalized

medicine products

include

innovative

molecular

diagnostic tests such as BRACAnalysis® that analyzes breast cancer genes to

assess a woman's risk for breast and ovarian cancer").

https://via.library.depaul.edu/jatip/vol20/iss2/9

26

Dunne: "Come, Let Us Return to Reason": Association of Molecular Patholo

2010]

ASS'N MOLECULAR BIOLOGY V, USPTO
B.

1.

499

Gene PatentsDo Not Violate the FirstAmendment

Gene Patents Do Not Cover Information

The ACLU's First Amendment argument alleges that the
challenged Myriad patents "directly limit thought and knowledge"
by encompassing pure thought and speech and as such are
unconstitutional under the First Amendment.14 8 This argument
lacks merit because it is "premised upon the false assumption that
the challenged patent claims cover 'information' and pure thought
'
or speech."149
In Judge Sweet stated in his opinion denying the
defendants' motions to dismiss: "[t]he challenges to the patents-insuit raise questions of difficult legal dimensions concerning
constitutional protections over the information that serves as our
genetic identities and the need to adopt policies that promote
scientific innovation in biomedical research" 150 This statement,
characterizing genes as information
rather than chemical
molecule, suggests that he may be more aligned with the ACLU's
argument that gene patents constitute a "monopoly on
information." This misguided interpretation of the patents-in-suit
could have potentially harmful implications on his ultimate ruling
on the plaintiffs' cause of action under the First Amendment. 51
The ACLU's argument, as well as Judge Sweet's interpretation,
is misfounded, because it fails to recognize the critical distinction
between "genes, which are chemical compounds, and genetic
sequences, which are human-created representations that identify
one of the gene's properties: the arrangement of nucleic acids in
the gene." '52 Gene patents do not claim pure information. What
148. The ACLU further alleges that broad restrictions on the use of genes is
tantamount to a restriction on thought and speech. See Myriad Memo, supra
note 1, at 41; see also Compl., supra note 4, 103 at 29.
149. MyriadMemo, supra note 1, at 5.
150. Order Denying Motion to Dismiss, supra note 12, at 2 (emphasis
added).
151. Plaintiff's First Amendment claim is based on the idea that gene patents

are essentially patents on information.
152. Defendant USPTO's Memorandum of Law In Support of its Motion for
Summay Judgment on the Pleadings And In Opposition to Plaintiffs' Motion for
Summary Judgment at 22, Ass'n for Molecular Pathology v. USPTO, No. 09-
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gene patents do claim are tangible chemical molecules. 153 Like
any other chemical compounds, DNA molecules are eligible for
patents when isolated from their natural state and purified. "I
The confusion regarding what DNA actually is, as well as what
gene patents actually claim, is attributable to the duality of DNA.
DNA is unique, in that it simultaneously acts as both a chemical
and as information. 55 While DNA is a chemical, it is more
complex in that its genetic sequence, is often viewed as an
embodiment of information. 156 Thus, many gene opponents argue
that patents should not be granted on genetic material because the
genetic sequences are information. Even Judge Sweet stated in his
opinion that "the widespread use of gene sequence information as
the foundation for biomedical research means that resolution of

4515
(S.D.N.Y.
filed
December
24,
2009),
available at
http://docs.justia.com/cases/federal/district-courts/new-york/nysdce/1:2009cv
04515/345544/176 (hereinafter USPTO Memo).
153. See Myriad Memo, supra note 1, at 5 ("The 'isolated DNA' claims
cover chemical compositions, not mere information, and the diagnostic method
claims cover physical laboratory testing. These claims do not prevent anyone
from thinking, speaking, or disseminating information."); see also USPTO
Guidelines, supra note 43, at com. 8 (affirming that "DNA, in its isolated and
purified form, "is a chemical compound and is patentable if all the statutory
requirements are met"); Myriad Memo, supra note 1, at 14 ("The term 'DNA'
stands for deoxyribonucleic acid. This 'acid' is a real and tangible molecule, a
chemical composition made up of deoxyribonucletides linked by a
phophodiester backbone").
154. USPTO Guidelines,supra note 43, comm. 2, at 1093.
155. Kevin Noonan, Anti-Patent ("Sullivan?") Malice by the New York
Times, PATENTDOCS.ORG, Jan. 29, 2007, http://www.patentdocs.org/2007/01/
antipatent sull.html.
156. USPTO Guidelines, supra note 43,cmt. 8; see also Declaration of
Joseph Straus, supra note 144, at 10 (stating "human genes are biochemical
substances as well as physical carriers of information"); Timothy A. Worral,
The 2001 PTO Utility Examination Guidelines and DNA Patents, 16 BERKELEY
TECH. L.J. 123, 125 (A gene is identified by a specific, ordered, sequence of
nucleotide bases (A, T, G, C) in a DNA strand); Debra Greenfield, Intangible
or Embodied Information: The Non-Statutory Nature of Human Genetic
Material, 25 SANTA CLARA COMPUTER & HIGH TECH. L.J. 467, 480 (2009)
("The sequencing of the bases is the medium through which DNA stores and
ultimately transmits information. " Furthermore, the DNA sequence, the
arrangement of these four bases is what "determines the nature, functionality,
and often the health of an organism").
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The

statement wrongly assumes that the BRCA patents at issue here
somehow claim fundamental information. However, a DNA
sequence itself is not patentable; the PTO issues patents on
isolated genes (i.e., on chemical compounds), not on genetic
sequences. 158
A DNA sequence is essentially "nonfunctional descriptive
information" that is represented by strings of the letters A, T, C,
and G. 159 Like any other descriptive property, patents are not
granted on genetic sequences. 160 In fact, full disclosure of the
patented genes is mandatory for the issuance of a gene patent. "An
isolated, purified and sequenced gene is more than just a DNA
sequence, and its utility goes beyond the information in its gene
sequence."' 61 Just because isolated nucleic acids might contain
information, it does not follow that that is all they are.16
2.

Gene patents Do Not Inhibit the Free-Flowof Information

The Patent Act provides that "[a]s a condition of issuance, all
patents must state precisely what the invention is, and fully
disclose sufficient information so that a person of average or
ordinary skill in the relevant technology area can make and use the
invention by reading the patent." 163 Additionally, the inventor
157. Order Denying Motion to Dismiss, supra note 12, at 2 (emphasis
added).

158.
159.
160.
161.

USPTO Memo, supra note 151, at 22.
USPTO Guidelines, supra note 43, cmt. 3 at 1093.
Id. at 1094 cmt. 8.
M. Scott McBride, Patentability of Human Genes: Our Patent System

Can Address the Issues Without Modification, 85 MARQ. L. REV. 511, 523
(2001).
162. Myriad Memo, supra note 1 (explaining that isolated DNA contains

uses much more extensive than just information and that isolated DNA's utility
is in its use as a molecular tool).
163. Andrew Beckerman-Rodau, The Supreme Court Engages in Judicial
Activism in Interpreting the Patent Law in Ebay, Inc. v. Mercexchange, L.L.C,
10 TUL. J. TECH. & INTELL. PROP. 165, 194 (2007); see 35 U.S.C. §112. The

enablement requirement is articulated in 35 U.S.C. § 112, 1, which states that a
patent applicant describe in the specification how to make and use the invention
claimed therein in such "full, clear, concise, and exact terms" as to permit any
person skilled in the art of the invention to do so without undue
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must disclose what he believes is the best way to make and use the
patented invention."6
This requirement is known as the
'disclosure requirement."65 In the case of gene patents, the
inventor is required to provide a "precise definition [of the DNA
molecule], such as by structure, formula, chemical name, or
physical properties."' 66
"Because the patent system requires public disclosure [of
patented inventions], it can promote a dissemination of scientific
and technical information that would not occur but for the prospect
of a patent."' 6 7 By promoting disclosure of inventions, patent law
stimulates "further innovation and permits the public to practice
the invention once the patent expires."' 68 Furthermore, disclosure
provides new opportunities for further development. Future
researchers may be advantaged by the starting point that the
original disclosure provides, they are able to discover higher,
better or more practical uses.'6 9 As a result, this mandatory
disclosure works to the betterment of society by increasing the
general knowledge of all researchers in the field and adding to the
experimentation. Id.
164. This is known as the best mode requirement. See 35 U.S.C. § 112
165. Sinclair & Carroll Co. v. Interchemical Corp., 325 U.S. 327; 330-31
(1945) ("The primary purpose of our patent system is not reward of the
individual but the advancement of the arts and sciences. Its inducement is
directed to disclosure of advances in knowledge which will be beneficial to
society") (citing Hartford-Empire Co. v. United States, 323 U.S. 386 (1945));
see also USPTO Memo, supra note 151 ("The disclosure required under the
patent system carries an additional benefit -- other researchers learn what has
been patented, and are therefore able to focus their research dollars on areas that
have yet to be explored").
166. Univ. of California v. Eli Lilly & Co., 119 F.3d 1559, 1568 (Fed. Cir.
1997); see 35 U.S.C. §112
I (setting forth the "written description"
requirement and the "enablement" requirement); see also, Noonan, supra note
134 (As a chemical, DNA can be protected by patent rights. However, as part
of the quid pro quo of thd patent system, the nucleotide sequence of a patented
gene must be disclosed, and that information is not patentable. So even while a
patent is in force, every researcher in the world can work to "design around" the
gene sequence to avoid infringement).
167. FTC, To PROMOTE INNOVATION: THE PROPER BALANCE OF
COMPETITION AND PATENT LAW AND POLICY at 5 (2003), available at http://
www.ftc.gov/os/2003/1 0/innovationrpt.pdf.
168. Aronson v. Quick Point Pencil Co., 440 U.S. 257, 262 (1979).
169. USPTO Guidelines, supranote 43, cmt. 7 at 1094.
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public storehouse of knowledge. 7 0
C. Gene patents and the Goals of the IP Clause

1.

Patents are not True Monopolies

The Supreme Court described the patent system as a "carefully
crafted bargain that encourages both the creation and the public
disclosure of new and useful advances in technology, in return for
an exclusive monopoly for a limited period of time.""17 This
utilitarian theory behind patent law views the short-term costs of
granting a limited monopoly as a necessary trade-off to obtain the
long-term benefits of incentivizing new and useful innovation.172
Though often so characterized a patent is not,
accurately speaking, a monopoly, for it is not
created by the executive authority at the expense
and to the prejudice of all the community except the
grantee of the patent. The term 'monopoly'
connotes the giving of an exclusive privilege for
buying, selling, working, or using a thing which the
public freely enjoyed prior to the grant. Thus a
monopoly takes something from the people. An
inventor deprives the public of nothing which it
enjoyed before his discovery, but gives something
of value to the community by adding to the sum of
human knowledge. He may keep his invention
secret and reap its fruits indefinitely. In
consideration of its disclosure and the consequent
benefit to the community, the patent is granted. An
exclusive enjoyment is guaranteed him for
seventeen years, but, upon the expiration of that
period, the knowledge of the invention inures to the
people, who are thus enabled without restriction to
practice it and profit by its use. To this end the law
170. Beckerman-Rodau, supra note163, at 195-96.
171. Pfaff, 525 U.S. 55, 63.
172. MUELLER, supra note 37, at 26-27.
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requires such disclosure to be made in the
application for patent that others skilled in the art
may understand the invention and how to put it to
use. 173
An important consideration often ignored in gene patent debates
is that patent rights are inherently limited in time, scope, and
exercise. 174 Patents do not confer any positive right to practice the
patented invention, but only provide the patent-holder "the right to
prevent others from using the patented invention without
authorization." 175 Furthermore, patents do not confer ownership of
genes, genetic information, or sequences as they occur in our
bodies. 176 19Once the patent term expires, the invention becomes
173. United States v. Dubilier Condenser Corp., 289 U.S. 178, 186-87 (1933)
(internal citations omitted).
174. See Kushan, supra note 69, at 18-19.
It should also be kept in mind that patent rights are inherently
limited; they give the owner of the patent the right to prevent
others from using the patent invention without authorization.
Patents do not convey positive rights to perform diagnostic
testing, impose impractical or unlawful conditions (through
contract or otherwise), or to waive compliance with laws
governing competition or regulation of human diagnostic
products. Patents only provide the right to prevent others
from using the patented invention.
Id.
175. Id. at 18.
176. "A patent is not a positive right to "perform diagnostic testing, impose
impractical or unlawful conditions (through contract of otherwise), or to waive
compliance with laws governing competition or the regulation of human
diagnostic products." Id.. at 19.; see also, NUFFIELD COUNCIL ON BIOETHICS,
supra note 21, ch.3, 3.7 at 22; NPR, Interview of Robin Feldman, Stanford
University Visiting Professor, Mar. 1, 2007, http://www.npr.org/templates/story/
story.php?storyld=7689495&ps--rs. Professor Feldman stated:
The gene as it exists in your body doesn't belong to anybody.
It's only as it exists in an isolated and purified form in a lab in
which we are doing something else with it.. .The problem
comes that once they start doing their research, then they run
into patent rights, and then they have some limitations on
what they would be able to do with it. But it's a little different
from the notion that someone can own what's in your body at
any point.
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available to anyone who wishes to make, use, or sell it.
2.

Gene Patents do not Inhibit Research

The ACLU alleges that gene patents should be declared
unconstitutional under the IP Clause on the grounds that that "the
patent claims in this case can be held as a matter of law to impede
'
rather than promote the progress of science"177
According to the
ACLU, the BRCA gene patents at issue "have deterred research
into this area critical for women's health," thus causing a "negative
impact on both breast and ovarian cancer research and clinical
'
practice."178
An efficient patent system will spur the incentive to make
scientific advancements or discoveries, not inhibit it. The ACLU
has provided no factual evidence to suggest this is not the case
with gene patents.'79 The defendants, on the other hand, have cited
numerous studies that suggest the exact opposite. Numerous
organizations have conducted a variety of studies that have led
them all to the same conclusion: patents do not hinder biomedical
innovation. 8 ' Some of the most notable of these organizations
177. Myriad Memo, supranote 1, at 5; U.S. Const. art. I, § 8, cl. 8.
178. P. 's Memo, supra notel9, at 5.
179. Smith, supra note 90, at 95 (quoting Gordon Arnold, chair of the ABA
Section of Intellectual Property Law as saying there is "zero evidence" that
patents or the patent system are hindering scientific research. "I think that over
time we will find that is a worry that was created by academics without
evidence, and patents have never discouraged innovation"; see also Chris
Holman, The Impact of Human Gene Patents on Innovation and Access: A
survey of Human Gene PatentLitigation, 76 UMKC L. REv. 295, 300 (2007)
("The paucity of documented examples in which the fears surrounding gene
patents have manifested themselves is striking, particularly when one considers
the high level of public concern and the extraordinary nature of the proposed
legislative fix").
180. See Timothy Caulfield, Intellectual Property: Do Gene Patents Hurt
Research? The Data Say they Don't, SCIENCE PROGRESS, Oct. 29, 2009,
http://www.scienceprogress.org/2009/10/do-gene-patents-hurt-research/;
see
also Myriad Memo, supra note 1, at 45 ("[A]n empirical study conducted at the
University of Illinois, which included a survey of 125 academic researchers
(including university, non-profit and government labs), demonstrated little to no
negative impact of patents on biomedical research productivity") (citing Straus
Decl. 44-47 ).
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have included the National Academy of Sciences, the American
Association for the Advancement of Science, and the Department
of Health and Human Services advistory committee. 1 '
The BRCA patents in particular have not been determined to
impede basic scientific research. A clear example of this is that
since Myriad's discoveries of the BRCA genes were made public
"over 18,000 scientists (including eight of the plaintiffs or their
declarants) have conducted research on the BRCA1 and BRCA2
genes, and have published more than 7,000 papers on those genes
82
since Myriad's patents were issued."'
3.

The Policy Debate

It is undeniable there are policy interests at stake for both sides
of the debate. Patents that claim innovative medical technologies
raise a multitude of new concerns. The long term goals of the
patent system do not always directly align with the short-term
needs of patients. Myriad is one example of this. As a result of
the BRCA patents, Myriad has the exclusive right to
commercialize the BRCA diagnostic test, thus, stifling all potential
competition. 183 As a result, the ACLU raises legitimate concerns
regarding individual breast cancer patients who personally could
not afford the test, or who were unable to get a second opinion
confirming the accuracy of the testing. 84 There is also concern
that these patents may reduce incentives to correct flaws in the
tests or to adopt new technologies.
Although the ACLU raises many legitimate public policy
concerns, these arguments do not warrant a categorical ban on all
181. Jim Greenwood, Opposing view: Patentspromote innovation, Exclusive
gene-based rights spur vital research and development, USA TODAY, June 6,
2009, http://blogs.usatoday.com/oped/2009/06/opposing-view-patents-promoteinnovation.html.
182. MyriadMemo, supranote 1, at 1.
183. The stifling of competition with regard to medical technologies draws
significant critique. See, e.g., Woollacott, supra note 9 (quoting Yvonne Cripps,
the Harry T Ice Professof of Law at Indiana University Maurer School of Law:
"The patents have already been questioned internationally because of their
fundamental importance ... they affect, in various ways, access to potentially
life-saving medical treatment.").
184. See P1. 's Memo, supranote 19, at 6.
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gene patents. A strong patent system is essential to continuing
these life-changing advancements in thd biotechnology field.
"[G]ranting patents in exchange for public
disclosure of inventions - including for nucleic acid
inventions that are new, useful, non-obvious and
adequately disclosed - reflects sound public policy.
The benefits after nearly 30 years of experience
cannot be contested - more than a thousand
companies, employing more than a million highly
skilled people, and producing hundreds of lifesaving and life-changing products and services.
Indeed, the biotechnology industry is proof that the
patent system is working as it should - promoting

billions of dollars of investments in crucially
important research and development, generating
millions of jobs, and delivering new hope to
patients and consumers. -185
An efficient patent system must always balance the varying
interests at stake. 86 As Myriad illustrates, this balance becomes
increasingly complex when patents enter the health care sector.
However, it is short-sighted for the ACLU to ignore the fact that
some type of legal protection over technological advancements is
necessary in order to continue research and development in the
Without intellectual property rights,
field of genetics.
biotechnology firms would likely avoid this type of work and
direct their energy and capital elsewhere.' 87
185. Kushan, supra note 69, at 19 (emphasis added).
186. NUFFIELD COUNCIL ON BIOETHICS, supra note 21, ch. 2, 2.3 at 12; see
also Melissa E. Horn, Note, DNA Patenting and Access to Healthcare:
Achieving the Balance Among Competing Interests, 50 CLEV. ST. L. REv. 253,
254 (2003-2003) ("The ultimate goal of patent law is to strike a balance between
providing rewards for invention, spurring new innovation, and ensuring the
availability of the innovations to the public.") (citing Brenner v. Manson, 383
U.S. 519, 533-535 (1966)).
187. Molly A. Holman & Stephen R. Munzer, IntellectualPropertyRights in
Genes and Gene Fragments: A Registration Solution for Expressed Sequence
Tags, 85 IOWA L. REv. 735, 827; see also, Human Genome Program, U.S.
Department of Energy, 11 Human Genome News n. 1-2, available at
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The nature of the biotechnology industry makes it particularly
dependent on patent protection. Biotechnology research and
development is routinely described "as a long-term, capitalintensive, and high-risk endeavor." '88 First, a private company's
decision to fund biotechnology research and development is not a
short-term investment. "New therapeutics typically take eight
years of clinical development, not to mention what often amounts
18
to years of pre-clinical research.""
Second, the investment
required in the biotechnology realm is staggering in comparison to
many other industries. Often, "hundreds of millions of dollars of
investment must precede the commercial launch of a product." 190
"The average capitalized cost of bringing a single biotechnologyrelated therapeutic to market exceeds $1.2 billion once the basic
research, clinical trials, and post-approval testing is combined." 19
Finally, even with patent protection, there is a risk that these
investments may never even pay off. "Only a minority of the
therapeutics that begin human clinical trials ultimately obtain FDA

http://www.oml.gov/sci/techresources/Human Genome/publicat/hgn/v 11 n 1/09b
ox.shtml ("Dennis Hopper (Genetech, Inc.) testified that his company invests
about $400million a year in the research and development of therapeutic
products, focusing on identifying human proteins. He said patent protection and
market exclusivity are very important considerations in making such
investments").
188. Letter
from
BIO
to
the
NIH,
available
at
http://bio.org/ip/domestic/documents/SACGHSBIOComments5-09.pdf;
see
generally, Jim Kling, Diagnosis or Drug? Will PharmaceuticalCompanies or
Diagnostics Manufacturers Earn More from Personalized Medicine?, Vol. 8
No. 10 EMBO REP. 903 (2007) (stating that "personalized medicine research
and developments are extremely costly and offer a very low rate of success").
189. BIO Brief supra note 11, at 19 (citing Henry Grabowski, Follow-On
Biologics: Data Exclusivity and the Balance Between Innovation and
Competition, Nature Reviews Drug Discovery at 3 (May 12, 2008)).
190. Id.at 15.
191. Id. at 19 (citing Grabowski, supra note 189, at 4); see also, Matthew
Hennessey, Patent Absurdity, Feb. 16, 2007 A publication of the Carnegie
Council (stating that to date, over $350 billion has been plunged into research
and development by the world's 4,000 biotechnology firms); BIO Brief supra
note 11, at 19 (citing ERNST & YOUNG, BEYOND BORDERS, GLOBAL
BIOTECHNOLOGY REPORT 2009 at 34) (stating that in 2008, more than $30
billion was invested in biotechnology-related research and development in the
United States alone)).
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approval." 192 Taking these factors into consideration, it is evident
why gene patents are a necessary tool to this burgeoning industry.
Patents need to be awarded in order to provide the original
inventor with the possibility to recoup the immense costs of
research. 93 Additionally, the recognizition of property rights in
new and useful biotechnology advancements provides these
investors with an incentive to continue to fund this research.
Without such protection, competitors could appropriate
economically valuable information without compensation.'94 As a
result, companies would be less willing to incur the costs of
investing in this research.'95 In the absence of an efficient patent
system,6 important research would result in a much slower pace, if
19
at all.
This decision to provide a means to generate investment in
biotechnology research has transformed a once highly speculative
science into an industry producing real-world products that have a
direct impact on public health. Patents help private firms recover
these high, fixed research and development costs.' 97 A researcher
will often utilize his or her patent in the initial stages of research as
a means to attract venture capital investment.' 98
This is
particularly true in the biotechnology industry. Intellectual
property rights are the main asset of innovative biotechnology
companies. 9 Weakening these rights will "make it much more
192. BIO Brief supra note 11, at 19.
193. USPTO Guidelines, supra note 43, at 1094.
194. Keith E. Maskus, Intellectual Property Rights and Economic
Development, 32 CASE W. RES. J. INT'L L. 471, 472 (2000).
195. Id.
196. Holman & Munzer, supra note 188, at 827.
197. See FEDERAL TRADE COMM., To PROMOTE INNOVATION: THE PROPER
BALANCE OF COMPETITION AND PATENT LAW POLICY 29(2003), available at

www.ftc.gov/os/2003/10/innovationrpt.pdf (stating that patents are especially
helpful to "enable biotechnology companies, which are generally small in size,
to attract capital investment and to contract with other firms for commercial
development of their inventions").
198. See Bio Letter, supra note 2, at 3 (noting that "[i]nvestors measure
opportunities in the biopharmaceutical sector through potential sales of the
drug/product, the strength of market protection from patents, and other forms of
exclusivity").
199. Id. at 11; see also BIO Brief supra note 11 ("Patents claiming isolated
DNA molecules are among the cornerstones of the intellectual property
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difficult to attract the massive capital investment required to
develop scientific discoveries into products that will benefit
patients. 200
Private companies, such as Myriad Genetics,
primarily through their own effort and expense have discovered,
isolated, and purified the genetic sequences of genes that are
known to correlate to hereditary illnesses. 20 ' As a practical
consideration, it is unrealistic to expect these companies to
continue investing effort and expense if they no longer have an
adequate means to protect this investment. 212 Thus, patents play a
large role in encouraging investment in biotechnology research
and are imperative to the industry's continued success. 3
Without the option of receiving protections via gene patents,
biotech companies are going to resort to other remedies to protect
the results of research in which they contributed large amounts of
financial investment as well as time and energy. Without the
possibility of receiving patent protection, biotechnology firms will
resort to protecting knowledge as a trade secret which would be
20 4
extremely disadvantageous to society.
V.

CONCLUSION

If the ACLU were to prevail and isolated genes were held to be
unpatentable, the consequences of such a holding would extend
devastatingly further than Myriad Genetics and the BRCA patents.
Without the ability to receive funding, the livelihood of the entire
biotechnology industry would be threatened. 5 Furthermore, this
portfolios" of many companies and academic institutions involved in the
research and development of biotechnology products).
200. Bio Letter, supranote 2, at 11.
201. Holman & Munzer, supra note 188, at 807-08.
202. Id.
203. In the present case, Myriad has invested more than $200 million just in
promoting patient access to BRCA testing. MyriadMemo, supra note 1, at 6.
204. See Holman & Munzer, supra note 188, at 740 (discussing tiny
fragments of genes known as expressed sequence tags (EST's): "[w]ithout
intellectual property rights (beyond trade secrets), biotechnology and
pharmaceutical firms have a strong incentive to keep their ESTs under lock and
key"); In re Shala, 996 F.2d 962, 965 (8th Cir. 1993) ("Patent issuance places
invention in public domain which destroys any trade secret rights").
205. Currently, the biotechnology industry has spurred the creation of jobs
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would eliminate patents currently held by public universities and
non-profit research entities, not just private corporations. 2 6 A ban
on gene patents would also threaten patents in the chemical and
pharmaceutical arts, e.g. recombinant forms of human insulin
(used to treat diabetes), human growth hormone (used to treat
growth defects), tissue plaminogen activator (used to treat heart
attacks), interferon (used to treat a variety of diseases and
disorders), follicle stimulating hormone (used in fertility
treatments), and erythropoietin (used to treat cancer and kidney
failure patients). °7
It is my hope that the judiciary and legislative branches will
have the foresight to realize the potentially devastating impacts
that would result if the entire practice of gene patenting were
banned. Results of this magnitude will require an extensive review
of the accuracy behind such contentions. Many of the ACLU's
contentions are misfounded, mistaken, or in some cases plainly
untrue. A decision of this magnitude should not be left resolved to
rash judgments based on emotional concerns.
Lauren M Dunne

for more than 7.5 million people in the U.S. The U.S. has approximately 650
companies in 46 states that work in the area of genetic diagnostics; see Bio
Letter, supra note 2.
206. Research conducted in public universities, by the U.S. Government, and
by non-profit entities all receive patent protection as well. Bayh-Dole Act, 35
U.S.C. § 202 (2006). The Bayh-Dole Act,enacted in 1980, "encouraged the
recipients of federal research funding, including academic research institutions,
to patent the results of their research and license these inventions and
discoveries to companies for further development." Johnston, supra note 59, at
S28.
207. USPTO Memo, supra note 151, at 20.
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